Brigham and Women’s Hospital’s Hospital and Celera Corporation Publish Results Demonstrating That Carriers of a Variant of the LPA Gene Have More Than Two-Fold Higher Risk of Major Cardiovascular Events and That This Risk is Eliminated by Aspirin Therapy

ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) and its collaborators at Brigham and Women’s Hospital today announced the publication of a paper reporting that a variant of the LPA gene is associated with a two-fold higher risk of major cardiovascular events (myocardial infarction, ischemic stroke and cardiovascular death). Prior studies from Celera and other collaborators also reported the association of this gene variant and cardiovascular risk. The newly published study confirmed the increased risk associated with this LPA variant and showed that the excess risk was eliminated by taking low dose aspirin. The paper is currently available on the journal’s website at http://atherosclerosis-journal.com/inpress.